News und Analysen
![Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program
![Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program
![Qiagen: Muss Thermo-Fisher jetzt nachbessern?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Qiagen: Muss Thermo-Fisher jetzt nachbessern?
Größter Gewinner im MDAX ist heute die Aktie des deutsch-niederländischen Biotechausrüsters Qiagen (WKN: A2DKCH). Grund hierfür sind die bereits gestern Abend überraschend vorgelegten vorläufigen
![Qiagen: Muss Thermo-Fisher jetzt nachbessern?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Qiagen: Muss Thermo-Fisher jetzt nachbessern?
Größter Gewinner im MDAX ist heute die Aktie des deutsch-niederländischen Biotechausrüsters Qiagen (WKN: A2DKCH). Grund hierfür sind die bereits gestern Abend überraschend vorgelegten vorläufigen
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Simulations Plus Reports Third Quarter FY2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Simulations Plus Reports Third Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported
![Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health
![Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health
![Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare
Regulatory News:
Transgene (Paris:TNG) and Hypertrust Patient Data Care today announced as a world premiere the first productive blockchain solution for clinical trials of personalized
![EOS imaging Announces the First EOSedge™ Installation in Germany](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
EOS imaging Announces the First EOSedge™ Installation in Germany
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), the leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical
![Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases
Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite
![Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases
Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite
![Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases
Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite
![Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)
![Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the
![NanoString to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NanoString to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release second quarter 2020
![EOS imaging: Availability of the 2019 Annual Financial Report in English](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EOS imaging: Availability of the 2019 Annual Financial Report in English
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning
![LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials1, which details the design for “A Prospective
![Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients
![STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that EVO Viva™, STAAR’s
![Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!
Starke Tinnitus-Daten schicken die Aktie von Otonomy (WKN: A119VZ) nachbörslich in die Höhe. Im No Brainer Club reißt die Erfolgsserie nicht ab. Wie geht es jetzt weiter?
Mit der Aktie von Otonomy
![Quidel Announces Preliminary Revenue for Second Quarter 2020](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Quidel Announces Preliminary Revenue for Second Quarter 2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
![Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Patrick F. Williams has
![GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
![Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on